BCLS Acquisition, a blank check company formed by Bain Capital Life Sciences targeting the healthcare industry, filed on Friday with the SEC to raise up to $125 million in an initial public offering.
The Boston, MA-based company plans to raise $125 million by offering 12.5 million shares at $10. The SPAC is not offering warrants that would become exercisable following completion of the initial business combination. It may raise an additional $25 million at the closing of an acquisition pursuant to a forward purchase agreement with its sponsor. At the proposed deal size, BCLS Acquisition would command a market value of $161 million.
The company is led by co-founders and Managing Directors of Bain Capital Life Sciences, Chairman Adam Koppel and CEO and Director Jeffrey Schwartz. The company plans to target the healthcare industry, particularly businesses based primarily based in North America and Europe in the biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology fields.
BCLS Acquisition was founded in 2020 and plans to list on the Nasdaq under the symbol BLSA. The company filed confidentially on September 17, 2020. Goldman Sachs and Jefferies are joint bookrunners on the deal.
The article Bain Capital's SPAC BCLS Acquisition files for a $125 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.